Newswise — New research by scientists at the University of Chicago suggests a person’s antibody response to influenza viruses is dramatically shaped by their pre-existing immunity, and that the quality of this response differs in individuals who are vaccinated or naturally infected. Their results highlight the importance of receiving the annual flu vaccine to induce the most protective immune response.
The researchers found that most of the initial antibodies stimulated after both influenza infections and influenza vaccinations came from old B cells — a type of white blood cell that secretes antibodies —indicating the immune system’s memory plays a major role in how the body responds early on to a viral infection. These antibodies displayed higher reactivity toward strains of influenza that circulated during an individual’s childhood compared to more recent strains.
The study, published December 10, 2020 in the journal Science Translational Medicine, provides those working on a universal influenza vaccine further understanding of how pre-existing immunity affects the development and performance of neutralizing and non-neutralizing antibodies following infection and vaccination. Any effective universal influenza vaccine will depend on scientists identifying ‘conserved’ parts of the influenza virus that do not mutate over time and that antibodies can target to prevent infection.
“Most interestingly, we found that people who were actively sick with influenza had old antibodies that predominantly targeted parts of the virus that don’t change — but those antibodies specifically targeted non-neutralizing sites,” said Haley Dugan, co-first author of the study and a PhD candidate in immunology. “When we tested these same antibodies in mice, they weren’t able to protect them from being infected with influenza.”
In contrast, the researchers found that influenza vaccinations boost antibodies that tended to target conserved yet neutralizing regions of the virus, which suggests vaccinations can draw upon pre-existing immunity to prompt more protective responses. Vaccinated individuals also generated many antibodies that targeted new and mutated regions on the virus, suggesting these vaccine-induced antibodies are more adaptable.
Immune system memory ensures a rapid and specific response to previously encountered pathogens. Vaccinations work by exposing the immune system to a small amount of virus, which causes B cells to develop a biological memory to the virus. If the body encounters the same virus later, the immune system is alerted to attack and eliminate the virus.
But in order to be protected, the viral proteins of the infecting strain must typically match those of the strain used in the vaccine. The memory B cells are like keys that fit and bind to the locks — the viral proteins. These memory B cells can survive for decades, providing long-lasting protection from future infections. But if the virus mutates and is significantly different, the memory B cells can no longer recognize the viral proteins, potentially leading to infection.
For this reason, the human body is pitted in an evolutionary arms race with the flu. Because influenza viruses rapidly evolve and mutate each season, our immune system has trouble recognizing the viral surface proteins on new influenza strains. As a result, our bodies often rely on old antibodies to fight new influenza strains; this is possible because some parts of the influenza virus that are critical to its structure or function do not change, remaining familiar to our immune system.
Researchers now understand that specific structural and functional parts of the influenza virus that do not change are better for antibodies to target than others. Antibodies that bind to one of these neutralizing sites are able to prevent infection, while antibodies that target non-neutralizing sites often cannot. Scientists believe a person’s age, history of exposure to the influenza virus and type of exposure — either through infection or vaccination — all shape whether their immune system antibodies target neutralizing or non-neutralizing sites on a virus.
In the UChicago study, scientists sought to address a major knowledge gap: Which conserved viral sites are preferentially targeted following natural infection versus vaccination in people, and how does pre-existing immunity play a role in shaping the landscape of neutralizing and non-neutralizing antibodies?
“For people who have caught the flu, their pre-existing immunity may make them susceptible to infection or increase the severity of their influenza symptoms if their antibodies are targeting ‘bad’ or non-neutralizing viral sites,” said co-first author and Immunology postdoctoral fellow Jenna Guthmiller, PhD.
By contrast, vaccination largely induces neutralizing and protective antibodies, old and new, highlighting the importance of receiving the seasonal influenza vaccine.
“This study provides a major framework for understanding how pre-existing immunity shapes protective antibody responses to influenza in humans,” said Patrick Wilson, PhD, a professor of immunology and lead author of the study. “We need more studies to determine whether the targeting of specific neutralizing and non-neutralizing viral sites directly impacts a person’s likelihood of becoming ill.”
The researchers are now examining how early exposure to the influenza virus in children shapes their immune response later in life as a follow-up to this work.
“Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans” was written by Patrick Wilson, Haley Dugan, Jenna J. Guthmiller, Philip Arevalo, Min Huang, Yao-Qing Chen, Karlynn Neu, Carole Henry, Nai-Ying Zheng, Linda Yu-Ling Lan, Micah Tepora, Olivia Stovicek, Dalia Bitar, Anna-Karin Palm, Christopher Stamper, Siriruk Changrob, Henry Utset and Sarah Cobey of the University of Chicago and Lynda Coughlan and Florian Krammer of the Icahn School of Medicine at Mount Sinai. The study was funded in part by the National Institute of Allergy and Infectious Disease and the University of Chicago Committee on Immunology.
About the University of Chicago Medicine & Biological Sciences
The University of Chicago Medicine, with a history dating back to 1927, is one of the nation’s leading academic health systems. It unites the missions of the University of Chicago Medical Center, Pritzker School of Medicine and the Biological Sciences Division. Twelve Nobel Prize winners in physiology or medicine have been affiliated with the University of Chicago Medicine. Its main Hyde Park campus is home to the Center for Care and Discovery, Bernard Mitchell Hospital, Comer Children’s Hospital and the Duchossois Center for Advanced Medicine. It also has ambulatory facilities in Orland Park, South Loop and River East as well as affiliations and partnerships that create a regional network of care. UChicago Medicine offers a full range of specialty-care services for adults and children through more than 40 institutes and centers including an NCI-designated Comprehensive Cancer Center. Together with Harvey-based Ingalls Memorial, UChicago Medicine has 1,296 licensed beds, nearly 1,300 attending physicians, over 2,800 nurses and about 970 residents and fellows.
Visit UChicago Medicine’s health and science news blog at www.uchicagomedicine.org/forefront.